Phase 3 Study of Ofev as Treatment for Progressive Fibrosing Lung Diseases Now Enrolling Patients
Idiopathic Pulmonary Fibrosis, News
The first patient has been enrolled in Boehringer Ingelheim’s Phase 3 clinical trial investigating the effectiveness and safety of Ofev (nintedanib) in progressive fibrosing interstitial lung diseases (PF-ILD). ILD encompasses a ... Read more